Also known as Foundayo · LY3502970 · OWL833
The first small-molecule (non-peptide) GLP-1 receptor agonist to reach approval — a once-daily pill with no food or water restrictions, FDA-approved as Foundayo for chronic weight management in April 2026.
Research refreshed
Orforglipron is not a peptide. It is a small organic molecule (~883 Da) that activates the same GLP-1 receptor as semaglutide, which is why it belongs in this reference: it is the non-peptide answer to the problems peptides create — injection, cold chain, and complex synthesis. Discovered by Chugai and developed by Eli Lilly, it is taken once daily by mouth without the fasting rules oral semaglutide requires. The FDA approved it as Foundayo for chronic weight management on April 1, 2026, on Phase 3 ATTAIN-1 data showing 12.4% mean weight reduction at 72 weeks on the highest dose versus 0.9% on placebo.
Every other GLP-1 agonist in this catalog is a peptide — a chain of amino acids that the gut digests, which is why they are injected (or, for oral semaglutide, co-formulated with an absorption enhancer and taken fasting with a sip of water). Orforglipron takes a different route entirely: it is a conventional small molecule, made by organic synthesis rather than peptide synthesis, that happens to switch on the GLP-1 receptor. It survives digestion, is absorbed like an ordinary tablet, and has a half-life of roughly 29–49 hours, supporting once-daily dosing at any time of day.
It was discovered at Chugai Pharmaceutical (as OWL833) and licensed to Eli Lilly in 2018. The Phase 3 program ran on two tracks. ATTAIN-1 (Wharton et al., NEJM 2025) randomized 3,127 adults with obesity or overweight and reported mean weight change at 72 weeks of −12.4% on the 36 mg dose versus −0.9% on placebo. ACHIEVE-1 (Rosenstock et al., NEJM 2025), in early type 2 diabetes, reported HbA1c reductions of 1.3–1.6 percentage points at 40 weeks. Those weight figures are below injectable semaglutide 2.4 mg and well below tirzepatide — the case for orforglipron is convenience and manufacturing scale, not peak efficacy.
The FDA approved orforglipron as Foundayo on April 1, 2026 for chronic weight management in adults with obesity, or overweight with a weight-related condition — the first new molecular entity cleared under the Commissioner’s National Priority Voucher pilot, after an unusually short review. The label carries the class boxed warning about thyroid C-cell tumors. A type 2 diabetes indication was being pursued separately on the ACHIEVE program; check the current label before relying on its status.
Non-peptide agonist of the GLP-1 receptor that binds within the transmembrane domain rather than at the peptide-binding site. Signaling is biased toward G-protein / cAMP activation with little β-arrestin recruitment. Downstream effects match the class: glucose-dependent insulin secretion, slowed gastric emptying, reduced appetite.
Behind every vial of Orforglipron is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Orforglipron, specifically, is brought into being.
On paper, Orforglipron is C48H48F2N10O5 — about 883 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Orforglipron is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Orforglipron plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Orforglipron proves itself: identity confirmed by mass spectrometry against its ~883 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Orforglipron — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Orforglipron to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Orforglipron, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Orforglipron (Foundayo) is a once-daily oral GLP-1 receptor agonist from Eli Lilly. Unlike semaglutide or tirzepatide it is a small molecule, not a peptide. The FDA approved it for chronic weight management in April 2026.
No. It is a small organic molecule (C48H48F2N10O5, about 883 Da) that activates the GLP-1 receptor. It is included in this peptide reference because it is the direct non-peptide counterpart to the GLP-1 peptides — same receptor, entirely different chemistry.
In ATTAIN-1 (NEJM 2025), adults on the highest dose lost a mean of 12.4% of body weight at 72 weeks versus 0.9% on placebo. That is less than injectable semaglutide 2.4 mg (~14.9% in STEP-1) or tirzepatide (~22.5% in SURMOUNT-1); the trials were not head-to-head. Population means, not individual predictions.
Oral semaglutide is a peptide co-formulated with the absorption enhancer SNAC and must be taken on an empty stomach with a small amount of water. Orforglipron is a small molecule absorbed like an ordinary tablet, with no food or water restrictions.
The same pattern as the injectable class — nausea, vomiting, diarrhea and constipation, mostly during dose escalation. The label carries the class boxed warning about thyroid C-cell tumors seen in rodents and advises against combining it with other GLP-1 therapies. This page is a research reference, not medical advice.
Peptide GLP-1 drugs need long solid-phase or recombinant synthesis, fatty-acid acylation, sterile injectable manufacturing and cold storage. A small molecule is made by conventional chemical synthesis and pressed into room-temperature tablets — far easier to scale.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.